ChiCTR2400081254
正在进行
万古霉素+美罗培南
/
万古霉素+美罗培南
2024-02-27
/
/
Sepsis
萬古黴素和美羅培南的藥代動力學研究和兒科先導抗生素導向計劃
萬古黴素和美羅培南的藥代動力學研究和兒科先導抗生素導向計劃
1. To provide evidence-based recommendation for vancomycin in paediatric patients by development of a local population pharmacokinetic model using vancomycin therapeutic drug monitoring 2. To provide evidence-based recommendation for continuous-infusion meropenem in paediatric patients by development of a local population pharmacokinetic model using meropenem therapeutic drug monitoring with the aim to predict T>MIC (percentage of time that drug concentration exceeds the MIC) 3. To evaluate the implementation of paediatric antibiotic stewardship program (ASP) in paediatric patients and the impact on microbiology and clinical outcomes , including the study of vancomycin dose optimization calculator guided by Bayesian estimated PK/PD target to estimate the 24-hour AUC/MIC (24 hour area under the concentration-time curve to MIC ratio) and evaluation of its impact on microbiology and clinical outcomes, including PK/PD attainment
横断面
其它
N/A
N/A
Department of Microbiology/CUHK
/
50;100
/
2024-03-01
2027-02-28
/
Inclusion criteria (Part 1): Patients in NICU and PICU and other paediatric units prescribed with intravenous vancomycin Inclusion criteria (Part 2): Patients in NICU and PICU and other paediatric units prescribed with intravenous meropenem Inclusion criteria (Part 3): Receipt of at least one of the selected antibiotics (intravenous vancomycin or intravenous meropenem) for at least 48 hours；
请登录查看Exclusion criteria (Part 1): Age more than 18 years Patients with extreme prematurity (born before 28 weeks of pregnancy) Subject’s parent or guardian who is not willing to sign informed consent Exclusion criteria (Part 2): Age more than 18 years Patients with extreme prematurity (born before 28 weeks of pregnancy) Subject’s parent or guardian who is not willing to sign informed consent Exclusion criteria (Part 3) Age more than 18 years；
请登录查看Department of Microbiology/CUHK
/
锦波生物2026-03-03
品牌共创局2026-03-03
GMP办公室2026-03-03
医耀科技创新骑手2026-03-03
一度医药2026-03-02
药时空2026-03-02
贝达药业2026-03-02
摩熵医药2026-03-02
摩熵医药2026-03-02
400-9696-311 转1
400-9696-311 转2
400-9696-311 转3
400-9696-311 转4
川公网安备51019002008863号
本网站未发布麻醉药品、精神药品、医疗用毒性药品、放射性药品、戒毒药品和医疗机构制剂的产品信息
“坚决打赢禁毒人民战争”专栏 法律法规 | 美、墨、欧盟管制品种
友情链接: 摩熵医药 摩熵医药企业版 摩熵化学MolAid 晓材Matmole 摩熵医学MedXYZ 载体质粒 觅健肿瘤互助 动脉网 药物百科 中国医疗人才网 医药招商网
